In conclusion and from a clinical point of view, biopsies from patients with locally advanced or metastatic GC should be tested for HER2 overexpression, as trastuzumab is indicated in HER2-positive tumors in combination with palliative chemotherapy. Here, ERBB2 is linked to gastric cancer.